Prolytic GmbH uses modern analytical methods to provide important information on the tolerability of active medical ingredients for humans.
Prolytic GmbH was formed in 2003 from parts of ASTA Medica AG – a subsidiary of Degussa AG. Prolytic co-founder and managing director Dr. Dorothee Krone already worked for ASTA Medica on the Campus Oberhafen site. She plans to return to the campus in 2018 with Prolytic GmbH, which specializes in bioanalytics and pharmacokinetics. In an interview, she talks about her company’s business field and plans for the new, yet well-known location.
What exactly happens in a laboratory for bioanalytics and pharmacokinetics
Whoever wants to bring a new drug onto the market must first know whether it is absorbed by the body at all and how high the concentration in the blood is. As a service provider, we determine with which dose the desired effect can be achieved. For this purpose, we perform exact plasma examinations using bioanalytical methods. Depending on the active ingredient, the methods and the equipment required for this differ considerably. The term pharmacokinetics refers to the processes that the substance undergoes in the body. We evaluate the results of the analysis mathematically, create time curves for the plasma concentration and thus determine the correct dose.
At what stage of the drug development process do you come into play?
Relatively early. Once a potential drug is discovered, the question arises as to how best to administer it to the body for absorption. Ideally, we accompany the development process from this point in time. It often takes three to five years for the drug to enter the clinical phase and another 5 – 10 years for it to reach the market. Many studies and approval procedures are meanwhile necessary. We are not only analytically active – we are also regularly consulted for expert opinions.
What are your plans for the future?
In the coming years we want to open up the field of molecular biology and offer analyses of DNA and RNA. For this, however, we need more space than is currently available to us. We will therefore move to the Oberhafen Campus in the first half of 2018.
How will your premises on campus be designed?
We can implement an intelligent concept on our new, larger areas. Our premises will then be divided into two areas. On the one hand there are the laboratory areas with the most diverse analysis devices, the work surfaces for pipetting and for working with radioactive substances, and on the other hand the offices. Demarcation is important, for example, to prevent infectious material from entering the offices. For the first time, we also have a large meeting room, which we can also use for customer meetings. BEOS AG is very anxious to meet our wishes and the cooperation is always very transparent. In addition, BEOS employees are well acquainted with the construction guidelines for laboratories – after all, they have already gained experience in this respect with the other laboratory tenants on the site.
What are the advantages of the laboratory location Campus Oberhafen?
All five founders of Prolytic were previously employed at ASTA Medica in the buildings of the Campus Oberhafen. So, in a way, we are returning to our roots. We can make optimum use of the existing infrastructure. One example: We maintain a close business relationship with Aeterna Zentaris GmbH, which also emerged from Asta Medica and is still located on campus. Losan Pharma GmbH is another customer with whom we cooperate. I am also happy about the faster Internet access we get on campus. I’m not an expert in this field – but our IT technician was quite excited when he learned about the possibilities at the new location.